STUDY SPACE
Vaccine Effectiveness Against Long COVID in Children

Vaccine Effectiveness Against Long COVID in Children

Volume 153, number 4, April 2024 | Hanieh Razzaghi, PhD, MPH, Christopher B. Forrest, MD, PhD, Kathryn Hirabayashi, MPH, Qiong Wu, PhD, Andrea J. Allen, MS, Suchitra Rao, MBBS, MScS, Yong Chen, PhD, H. Timothy Bunnell, PhD, Elizabeth A. Chrischilles, PhD, Lindsay G. Cowell, PhD, MS, Mollie R. Cummins, PhD, RN, David A. Hanauer, MD, MS, Miranda Higginbotham, MSHA, Benjamin D. Horne, PhD, MStat, MPH, Carol R. Horowitz, MD, MPH, Ravi Jhaiveri, MD, Susan Kim, MD, MMSc, Aaron Mishkin, MD, Jennifer A. Muszynski, MD, MPH, Susanna Naggie, MD, MHS, Nathan M. Pajor, MD, MS, Anuradha Paranjape, MD, MPH, Hayden T. Schwenk, MD, MPH, Marion R. Sills, MD, MPH, Yacob G. Tedla, PhD, David A. Williams, PhD, L. Charles Bailey, MD, PhD, on behalf of the RECOVER CONSORTIUM
This study aimed to estimate the vaccine effectiveness (VE) against long COVID in children aged 5 to 17 years. The retrospective cohort study used data from 17 health systems in the RECOVER PCORnet electronic health record program. The vaccination rate was 67% among the cohort of 1,037,936 children. The incidence of probable long COVID was 4.5% among patients with COVID-19, while diagnosed long COVID was 0.8%. Adjusted VE within 12 months was 35.4% against probable long COVID and 41.7% against diagnosed long COVID. VE was higher for adolescents (50.3%) than for children aged 5 to 11 (23.8%). VE was higher at 6 months (61.4%) but decreased to 10.6% at 18 months. The study concluded that the SARS-CoV-2 vaccine has a moderate protective effect against long COVID, with stronger effects in adolescents and waning over time. Further research is needed to understand the mechanisms of VE against long COVID.This study aimed to estimate the vaccine effectiveness (VE) against long COVID in children aged 5 to 17 years. The retrospective cohort study used data from 17 health systems in the RECOVER PCORnet electronic health record program. The vaccination rate was 67% among the cohort of 1,037,936 children. The incidence of probable long COVID was 4.5% among patients with COVID-19, while diagnosed long COVID was 0.8%. Adjusted VE within 12 months was 35.4% against probable long COVID and 41.7% against diagnosed long COVID. VE was higher for adolescents (50.3%) than for children aged 5 to 11 (23.8%). VE was higher at 6 months (61.4%) but decreased to 10.6% at 18 months. The study concluded that the SARS-CoV-2 vaccine has a moderate protective effect against long COVID, with stronger effects in adolescents and waning over time. Further research is needed to understand the mechanisms of VE against long COVID.
Terms of Service
Privacy Policy
Reach us at info@study.space
Understanding Vaccine Effectiveness Against Long COVID in Children.